StockDuty ← Dashboard Aug 06, 2026 10:49 PM ET
SignalCorporate

NOVAVAX EXPECTS $235M-$275M IN 2026 ADJUSTED TOTAL REVENUE WHILE TARGETING $150M-$200M IN 2028 NON-GAAP R&D AND SG&A - SEEKINGALPHA

NOVAVAX EXPECTS $235M-$275M IN 2026 ADJUSTED TOTAL REVENUE WHILE TARGETING $150M-$200M IN 2028 NON-GAAP R&D AND SG&A - SEEKINGALPHA

What changed
Why it matters
Sources
seekingalpha
Related signals
FITCH AFFIRMS CHINA CREDIT RATING AT 'A' →FITCH ISSUES NEW STATEMENT AND OUTLOOK ON U.S . CREDIT RATING DEBT WARNING IN FIRST PARAGRAPH . →STRATEGY EXPANDS STRC PREFERRED STOCK BUYBACK PROGRAM; SHARES DOWN - SEEKINGALPHA →